These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280 [TBL] [Abstract][Full Text] [Related]
14. [[Gene expression of key enzymes for all-trans- retinoic acid biosynthesis - ALDHJAI and RDH10: relationship with co-expression of nuclear receptors RARα and PPARβ/δ genes and some clinical characteristics in multiple myeloma]. Kalitin NN; Chernykh YB; Buravtsova IV Vopr Onkol; 2016; 62(5):626-631. PubMed ID: 30695588 [TBL] [Abstract][Full Text] [Related]
15. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891 [TBL] [Abstract][Full Text] [Related]
16. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890 [TBL] [Abstract][Full Text] [Related]
17. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience. López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899 [TBL] [Abstract][Full Text] [Related]
18. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. Jung SH; Kim K; Kim JS; Kim SJ; Cheong JW; Kim SJ; Ahn JS; Ahn SY; Yang DH; Kim HJ; Lee JJ Br J Haematol; 2018 Jun; 181(5):707-710. PubMed ID: 28466549 [No Abstract] [Full Text] [Related]
19. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Jost E; Gezer D; Wilop S; Suzuki H; Herman JG; Osieka R; Galm O Cancer Lett; 2009 Aug; 281(1):24-31. PubMed ID: 19299079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]